Amarin Corporation plc Message Board
- Reply to
Now That NCE " Thing " Over ,,Back to $8 on AMRN Increasing Sales... read
by sharkman683 •May 17, 2013 2:33 PMshark.. how much you in for ? I'll send you my email.
- Reply to
Game Over for Lovaza= Lovaza RAISES LDL 45%, Vascepa Lowers LDL. LINK.
by sharkman683 •May 17, 2013 2:35 PMgreat info..!!
- Reply to
Now That NCE " Thing " Over ,,Back to $8 on AMRN Increasing Sales... read
by sharkman683 •May 17, 2013 2:33 PMthis is how we do it.. time to get back in cheap !
-
Good Luck All.
- Reply to
LINK TO INSIDERS SELLING, LONG LIST. SELLING AT $2.72
by tradinghulkman •May 15, 2013 11:56 AMthere is no reason they HAD to sell except they don't have much confideance in this drug. Will Not Buy.
-
Fly On The Wall After Hours 8:42 P.M.
May 16, 2013
08:42 EDT HALO Halozyme data favorable, says JMP Securities
JMP Securities was highly encouraged by data from a Phase I trial of Halozyme's PEGPH20 in pancreatic cancer, as the drug generated response rates that were significantly higher than competing drugs,according to the firm. JMP Securities raised its target on Halozyme to $12 from $10 and reiterates an Outperform rating on the shares - Reply to
When The VP of Clinical Oncology Says Study CLEARLY Reinforces HALO Drug, I Buy.
by supermanjoe •May 16, 2013 12:47 PMadded. thanks
-
wow desperate short or wants in cheap.
- Reply to
Pet Scan High False Pos Rate SO Survival Best Measure of Panc Ca RX- PEG INCREASED
by fezziwig2008 •May 16, 2013 12:31 PMfezzi your an idiot posting something from 2006 !!!!!!!!!!!!!!!!
- Reply to
Charts showing if $8 resistance broke, next resistance is $9.
by raytrader362 •May 16, 2013 11:36 AMcorrect sir.
- Reply to
been trying to get in all day, good entry point here before Asco.
by chrislawyerman •May 16, 2013 12:20 PMSuper. Likes.
-
why would that be ?
-
- Reply to
LINK TO INSIDERS SELLING, LONG LIST. SELLING AT $2.72
by tradinghulkman •May 15, 2013 11:56 AMnot a good sign
- Reply to
Game Over For Lovaza- Lovaza RAISES LDL Up 45%, Vascepa Lowers LDL. LINK
by fromnyjohn •May 14, 2013 11:42 AMdo the DD. Investors know this is a better drug thanLovaza.
-
By GlobeNewswire
"This sNDA approval of BASF as a supplier of Vascepa follows the recent sNDA approval to add Chemport, Inc. as a Vascepa API supplier and brings the number of approved Vascepa API suppliers to three. The BASF approval represents an additional step toward the goal of expanding our global supply chain tosupport expected Vascepa demand, diversify our supply base, and ensure cost-efficient supply. In addition, Amarin has plans for the submission of a fourth planned supplier in 2013. - Reply to
NO Dr's Will Prescribe Lovaza That Raises LDL 45%, When Vascepa Lowers LDL. READ
by supermanjoe •May 14, 2013 12:01 PMnot taking that long, AMRN sales are tripling month to month
-
Thank You Previous Poster-
Google to Verify
Lovaza has also been demonstrated to reduce VLDL-cholesterol and non-HDL-cholesterol, and increase HDL-cholesterol. But, it can raise LDL-cholesterol up to 45% Vascepa will undoubtedly become a major competitor for Lovaza.[6] In clinicial trials, Vascepa was shown to lower triglycerides; while Lovaza also lowers the triglyceride concentration, Vascepa also lowers LDL-C; Lovaza does not. Lovaza was approved to treat people with very high triglyceride levels ( 500 mg/dl), Vascepa is also approved for this market; however the company has also demonstrated that the drug can impact levels in people with high triglyceride ( 200 mg/dl and